Cagrilintide and semaglutide combine into CagriSema, an investigational once-weekly shot for obesity. Here's how it works, trial results, and safety.
Cagrilintide and semaglutide are two separate injectable drugs that Novo Nordisk combines into one once-weekly treatment called CagriSema. Semaglutide is an FDA-approved GLP-1 receptor agonist sold as Ozempic, Wegovy, and Rybelsus, while cagrilintide is an investigational amylin analog that no regulator has approved for human use. The combination hits two appetite-regulating hormone pathways at once, and in Phase 3 trials it delivered greater average weight loss than semaglutide alone.
What Are Cagrilintide and Semaglutide?
These are not two versions of the same molecule. They belong to different drug classes and work through different receptors, which is exactly why researchers study them together.
Semaglutide: the GLP-1 component
Semaglutide mimics glucagon-like peptide-1, a gut hormone that slows stomach emptying, increases fullness, and improves blood sugar control. It is approved as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management in adults and adolescents age 12 and older.
Cagrilintide: the amylin component
Cagrilintide is a long-acting analog of amylin, a hormone the pancreas releases alongside insulin after meals. Amylin slows gastric emptying and signals satiety through receptors that GLP-1 drugs do not touch. You will often see the pair written as the cagrilintide–semaglutide peptide, which is shorthand for the fixed-dose combination rather than a single new molecule.
| Feature | Semaglutide | Cagrilintide |
|---|---|---|
| Drug class | GLP-1 receptor agonist | Amylin analog |
| Hormone mimicked | GLP-1 | Amylin |
| Regulatory status | Approved (Ozempic, Wegovy, Rybelsus) | Investigational; not approved |
| Dose used in CagriSema trials | 2.4 mg once weekly | 2.4 mg once weekly |
| Most common side effects | Nausea, vomiting, diarrhea, constipation | Nausea, vomiting, constipation, injection-site reactions |
Why Combine Cagrilintide With Semaglutide?
Body weight is regulated by several hormones at once, and targeting only one of them leaves the body room to compensate. Semaglutide covers the GLP-1 pathway; cagrilintide adds amylin signaling. Early-phase data suggested that adding cagrilintide to semaglutide lowered body weight more than either drug alone.
Novo Nordisk is developing cagrilintide with semaglutide under the name CagriSema. Searches for cagrilintide semaglutide trade names usually lead back to Ozempic, Wegovy, and Rybelsus, because cagrilintide has no brand name of its own and is not sold anywhere as a standalone product.
What Do the Phase 3 Trials Show?
Two large Phase 3 trials anchor the evidence so far, both with a 68-week treatment period.
- REDEFINE 1 enrolled roughly 3,400 adults with obesity or overweight plus at least one related condition, none with type 2 diabetes. CagriSema produced about 22.7% average weight loss among participants who stayed on treatment, compared with about 11.8% for semaglutide 2.4 mg and 2.3% for placebo.
- REDEFINE 2 enrolled adults with type 2 diabetes and overweight or obesity. CagriSema produced roughly 13.7% weight loss at 68 weeks versus about 3.4% for placebo.
| Trial | Population | Duration | CagriSema result | Comparator result |
|---|---|---|---|---|
| REDEFINE 1 | Obesity or overweight, no diabetes | 68 weeks | ~22.7% weight loss (on treatment) | Semaglutide 2.4 mg: ~11.8%; placebo: ~2.3% |
| REDEFINE 2 | Type 2 diabetes plus overweight or obesity | 68 weeks | ~13.7% weight loss | Placebo: ~3.4% |
One important caveat: in REDEFINE 1, fewer than two-thirds of participants reached the highest 2.4 mg/2.4 mg dose, and the intention-to-treat figure was closer to 20%. Dose escalation and tolerability, not just peak efficacy, will determine how useful CagriSema proves in real-world practice.
How Does CagriSema Compare With Other Weight-Loss Drugs?
Indirect comparisons are tempting but unreliable, because trial populations, dosing protocols, and analysis methods differ. The table below shows the ballpark figures reported in each program's pivotal trial.
| Treatment | Class | Average weight loss in pivotal trial | Status in the US |
|---|---|---|---|
| Semaglutide 2.4 mg (Wegovy) | GLP-1 agonist | ~15% (STEP 1, 68 weeks) | Approved |
| Tirzepatide 15 mg (Zepbound) | GIP/GLP-1 dual agonist | ~21% (SURMOUNT-1, 72 weeks) | Approved |
| Cagrilintide plus semaglutide (CagriSema) | Amylin analog plus GLP-1 agonist | ~22.7% on treatment (REDEFINE 1, 68 weeks) | Investigational |
CagriSema has not been tested head-to-head against tirzepatide in a completed Phase 3 trial, so no one can say which one is more effective. Patients also frequently ask can you take semaglutide and tirzepatide at the same time — the answer is generally no, because guidelines call for one incretin-based drug at a time to avoid stacking side effects.
Side Effects and Safety Considerations
Gastrointestinal effects dominate the side-effect profile of both components.
- Nausea, vomiting, diarrhea, and constipation are the most frequently reported problems.
- Injection-site reactions appear more often with amylin analogs.
- Rare but serious risks with semaglutide include pancreatitis, gallbladder disease, and a boxed warning for thyroid C-cell tumors observed in rodents.
- Rapid weight loss can reduce lean muscle mass, so adequate protein intake and resistance training matter.
Alcohol is not a pharmacological contraindication with semaglutide, but drinking can worsen nausea and adds empty calories, a theme that comes up often in discussions about semaglutide and alcohol. Anyone considering these medications should review their full medication list and health history with a licensed healthcare professional.
It also helps to keep the evidence hierarchy in mind. People researching metabolic peptides often compare aod 9604 and semaglutide, but AOD-9604 is not FDA-approved for weight loss and has far thinner human data. Reviews of aod-9604 benefits and side effects consistently note that the compound's clinical evidence is not comparable to that of approved GLP-1 medications.
Is CagriSema Available in the United States?
No. Cagrilintide is not approved by the FDA, and CagriSema is not sold in pharmacies. Novo Nordisk has said it intends to seek regulatory approval after the REDEFINE program concludes, but no filing has been cleared as of this writing.
Products marketed online as "CagriSema" or "cagrilintide peptide" are almost always unverified research chemicals with no guarantee of identity, purity, or sterility. The same caution applies to any gray-market injectable, whether someone is searching for where to buy bpc-157 and tb-500 or shopping for compounded GLP-1 products.
Frequently Asked Questions
Is CagriSema the same thing as Ozempic or Wegovy?
No. Ozempic and Wegovy contain semaglutide alone, while CagriSema combines semaglutide with cagrilintide, an amylin analog, in a single weekly injection. CagriSema is still investigational and has not been approved by the FDA.
How much weight do people lose on cagrilintide and semaglutide?
In the REDEFINE 1 trial, adults without diabetes lost about 22.7% of their body weight on treatment at 68 weeks, compared with roughly 11.8% on semaglutide 2.4 mg and 2.3% on placebo. In REDEFINE 2, which enrolled people with type 2 diabetes, average weight loss was about 13.7% versus 3.4% for placebo. Individual results vary widely.
Can I buy cagrilintide semaglutide peptide online?
Not as a legitimate finished medication. Cagrilintide is not approved for human use, so any product sold online as CagriSema or cagrilintide peptide is an unregulated research chemical with unverified purity and sterility. If you are seeking treatment for obesity or type 2 diabetes, talk to a licensed clinician about FDA-approved options.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.